Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3536820A vs Menveo in Healthy Adults
NCT03652610Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2018
- Primary completion
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, triple-blind trial of Meningococcal A, C, Y and W-135 conjugate vaccine in meningococcal infection (2 arms), sponsored by GSK. Primary endpoint: Adjusted Human Serum Bactericidal Activity Geometric Mean Titers Against N. Meningitidis Serogroup A at Day 29. Started Sep 2018; status: completed.
02
Drugs
Meningococcal A, C, Y and W-135 conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT03652610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652610.